JIA-associated uveitis

JIA-associated uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis and the leading cause of preventable blindness in children in developed countries. It occurs predominantly in oligoarticular and RF-negative polyarticular JIA subtypes, characteristically presenting as chronic, asymptomatic anterior uveitis without the red eye or pain that typifies adult uveitis. The insidious, asymptomatic nature of JIA uveitis means it is only detected through systematic slit-lamp surveillance, and delayed diagnosis leads to cumulative ocular damage including posterior synechiae, band keratopathy, cataract, glaucoma, and ultimately permanent visual impairment. Uveitis occurs in approximately 12–20% of oligoarticular JIA and 10–20% of RF-negative polyarticular JIA patients, with the highest risk in young females who are ANA positive.

JIA-associated uveitis is an autoimmune T cell-mediated inflammatory condition of the uveal tract (iris, ciliary body, choroid). The pathogenesis involves autoreactive T cells targeting uveal antigens, with ANA positivity indicating a breakdown of B cell tolerance that correlates with higher uveitis risk.

Immunological Mechanisms

• T cell-mediated uveal inflammation — CD4+ T cells infiltrate the anterior uveal tract; regulatory T cell dysfunction allows autoreactive T cell expansion targeting uveal antigens including S-antigen and interphotoreceptor retinoid-binding protein
• ANA and uveitis risk — ANA positivity reflects B cell dysregulation; ANA titre ≥1:160 doubles uveitis risk; ANA-positive children have earlier uveitis onset and more severe course
• TNF-α and IL-6 — pro-inflammatory cytokines elevated in aqueous humour of JIA uveitis; TNF inhibition (adalimumab) suppresses intraocular inflammation; IL-6 blockade (tocilizumab) is an emerging option for refractory uveitis
• Blood-ocular barrier disruption — breakdown of the blood-aqueous barrier allows inflammatory cells and proteins to accumulate in the anterior chamber; cell and flare grading (Tyndall effect) reflects barrier disruption and is the key measure of uveitis activity

Risk Factors for JIA Uveitis

• Oligoarticular JIA subtype — highest uveitis prevalence (15–30%); extended oligoarticular JIA has similar risk to persistent
• ANA positivity — most significant modifiable risk factor; ANA-positive oligoarticular JIA has ~25% uveitis risk; ANA-negative has ~5%
• Young age at JIA onset — onset before age 7 years confers highest uveitis risk; uveitis risk decreases with older age at JIA onset
• Female sex — higher uveitis prevalence in girls with oligoarticular JIA; male ERA patients have acute HLA-B27 uveitis instead
• Short duration between JIA and uveitis onset — uveitis commonly develops within the first 4–7 years of JIA diagnosis; peak risk in the first 2 years

The hallmark of JIA-associated uveitis is its asymptomatic, insidious presentation. Children do not complain of eye pain, redness, or photophobia. Visual blur may not be noticed until significant damage has occurred. The only reliable method of detection is slit-lamp biomicroscopy by an ophthalmologist.

Symptoms (or Absence Thereof)

• Asymptomatic — the vast majority of active JIA uveitis episodes are detected only on slit-lamp examination; no redness, pain, photophobia, or visual blurring until complications develop
• Blurred vision — may be noticed only when visual acuity is significantly impaired; indicates established damage (cataract, band keratopathy, macular oedema)
• Photophobia and redness — may emerge if posterior synechiae cause fixed mydriasis or if secondary glaucoma is severe; these are LATE signs in JIA uveitis

Slit-Lamp Findings

• Anterior chamber cells — white blood cells visible in aqueous humour; graded 0–4+ (SUN criteria); Grade 2+ (6–15 cells per high-power field) or above indicates active uveitis requiring treatment escalation
• Flare (Tyndall effect) — protein leak into aqueous humour; graded 0–4+; persistent flare despite cell clearance may indicate structural damage
• Keratic precipitates (KP) — inflammatory cell deposits on corneal endothelium; fine KP typical of JIA uveitis; mutton-fat KP suggests granulomatous (sarcoid, TB) uveitis
• Posterior synechiae — adhesions between iris and anterior lens capsule; result from chronic inflammation; distort pupil; risk of angle closure glaucoma

Complications of Uncontrolled Uveitis

• Band keratopathy — calcium deposits in Bowman layer of cornea; white, chalk-like opacity across the visual axis; reduces visual acuity; treated with EDTA chelation
• Cataract — posterior subcapsular cataract from chronic inflammation and/or corticosteroid use; most common cause of visual impairment in JIA uveitis; requires cataract surgery when visually significant
• Glaucoma — secondary to synechiae-related angle closure or steroid-induced; may be difficult to manage; trabeculectomy or glaucoma drainage device if medical therapy fails
• Macular oedema — less common in JIA uveitis than in other forms of uveitis; causes central visual loss; detected on OCT; indicates severe active uveitis
• Hypotony — ciliary body inflammation reduces aqueous production; persistent hypotony leads to phthisis bulbi

Investigations in JIA uveitis serve to confirm the diagnosis, assess severity, monitor complications, and guide treatment. The primary investigation is the slit-lamp examination with standardised cell and flare grading.

• Essential
  Slit-lamp biomicroscopy (anterior segment)

  The definitive investigation. Grading by SUN (Standardisation of Uveitis Nomenclature) criteria: anterior chamber cells (0 to 4+) and flare (0 to 4+). Grade 0.5+ = 1–5 cells (trace); Grade 1+ = 6–15 cells; Grade 2+ = 16–25 cells (active); Grade 3+ = 26–50 cells; Grade 4+ = >50 cells. Active uveitis: ≥0.5+ cells. Inactive uveitis: Grade 0. Uveitis grading guides treatment frequency and escalation. Must be performed by an ophthalmologist; GP ophthalmoscope is inadequate for anterior chamber assessment.
• Essential
  Intraocular pressure (IOP) measurement

  Elevated IOP (>21 mmHg) indicates steroid-induced or secondary angle-closure glaucoma — a vision-threatening complication requiring IOP-lowering treatment. IOP must be measured at each ophthalmology visit. Paradoxically, low IOP with active uveitis (hypotony) indicates ciliary body insufficiency.
• Essential
  Visual acuity testing

  Documented at each visit; decline indicates clinically significant uveitis complications. Age-appropriate visual acuity charts used (Snellen, LogMAR, Teller). Amblyopia risk in preschool children with unilateral or asymmetric uveitis.
• Recommended
  Optical coherence tomography (OCT)

  Detects macular oedema (thickening of macula on cross-sectional imaging) — a serious complication of severe uveitis. Not routinely available in all centres; performed when macular involvement is suspected or vision is unexpectedly reduced. Also used to monitor response to systemic treatment in macular oedema.
• Recommended
  ANA (antinuclear antibody)

  Guides uveitis surveillance frequency. ANA-positive children require more frequent slit-lamp examinations. Tested at JIA diagnosis; does not require routine repeating. Low-titre positive ANA (1:40–1:80) requires clinical interpretation in context.

Uveitis surveillance frequency is stratified based on JIA subtype, ANA status, age at onset, and disease duration. The 2019 ACR/AF guideline provides specific frequency recommendations.

Treatment of JIA uveitis follows a stepwise approach: topical corticosteroids for acute inflammation control, methotrexate as the systemic steroid-sparing agent, and adalimumab for MTX-refractory or severe uveitis.

Complications of JIA uveitis require specific directed management in addition to systemic anti-inflammatory therapy.

Band Keratopathy

• EDTA chelation — ethylenediaminetetraacetic acid (EDTA) applied to superficial cornea under topical anaesthesia; removes calcium deposits; procedure repeated as needed; improves visual acuity when band keratopathy is visually significant
• Excimer laser phototherapeutic keratectomy (PTK) — alternative to EDTA for recurrent or dense band keratopathy; specialist cornea procedure

Cataract

• Uveitis quiescence before surgery — cataract surgery in active uveitis has high complication rate; uveitis should be controlled (Grade 0 cells for ≥3 months) before elective cataract extraction
• Paediatric cataract surgery — performed by paediatric ophthalmologist; intraocular lens (IOL) implantation deferred in very young children due to risk of further inflammation; optical correction with contact lenses or glasses post-surgery
• Systemic immunosuppression perioperatively — increase systemic and topical anti-inflammatory therapy peri-operatively to reduce risk of severe post-operative uveitis flare

Glaucoma

• Topical IOP-lowering agents — beta-blockers (timolol), carbonic anhydrase inhibitors (dorzolamide), prostaglandin analogues; ophthalmologist directed
• Glaucoma surgery — trabeculectomy or glaucoma drainage implant (Baerveldt, Ahmed valve) for medically refractory glaucoma; higher failure rate in uveitic glaucoma compared to primary open angle glaucoma

Posterior Synechiae

• Mydriatic cycloplegics — topical cyclopentolate or atropine to dilate the pupil and prevent new synechiae formation; breaks early synechiae if caught promptly
• Intensive topical steroid pulse — hourly prednisolone acetate for active inflammation concurrent with synechiae development; arrest progression

The frequency of ophthalmological surveillance for JIA uveitis is determined by JIA subtype, ANA status, age at onset, and disease duration. The 2019 ACR/AF uveitis guideline provides evidence-based recommendations that are the standard of care in Australia.

Oligoarticular and RF-Negative Polyarticular JIA

• ANA-positive, onset age <7 years, disease duration <4 years: every 3 months
• ANA-positive, onset age <7 years, disease duration ≥4 years: every 6 months
• ANA-positive, onset age 7–11 years, disease duration <4 years: every 6 months
• ANA-positive, onset age 7–11 years, disease duration ≥4 years: every 12 months
• ANA-negative, all ages: every 12 months

Other JIA Subtypes

• Systemic JIA: every 12 months (low uveitis risk)
• ERA: annual slit-lamp; acute anterior uveitis (HLA-B27 type) is symptomatic and warrants urgent same-day ophthalmology when symptomatic
• Psoriatic JIA: same schedule as oligoarticular JIA based on ANA status

After Uveitis Diagnosis

• Active uveitis — every 4–6 weeks until sustained remission (≥3 months of Grade 0 cells)
• In remission on treatment — every 3 months; must not extend intervals during active systemic disease
• In remission off treatment — every 6 months for 2 years, then annually
• Uveitis can outlast articular disease — ophthalmology surveillance must continue even when joints are in remission

Monitoring in JIA uveitis encompasses ocular disease activity, structural complications, treatment toxicity, and systemic disease activity.

When to Refer Urgently

• New vision loss in a JIA patient: Sudden reduction in visual acuity — urgent ophthalmology same day; may indicate cataract, glaucoma, or macular oedema
• Symptomatic uveitis in ERA (HLA-B27 AAU): Red, painful, photophobic eye — same-day ophthalmology; different treatment from JIA chronic uveitis but equally urgent
• Elevated IOP on topical steroids: IOP >25 mmHg — ophthalmology review within 1 week; may require cessation of topical steroid or IOP-lowering therapy

Specific clinical considerations apply in particular patient groups with JIA uveitis.

Very Young Children (Age <4 Years)

• Highest uveitis risk — oligoarticular JIA onset before age 4 with ANA positivity carries the highest uveitis risk; earliest and most frequent surveillance required
• Amblyopia — unilateral active uveitis in young children causes deprivation amblyopia; visual development is complete by age 7–8; amblyopia treatment (patching) must be coordinated with uveitis treatment
• Slit-lamp examination under sedation — may be required for preschool children; ophthalmology and anaesthesia coordination needed

Uveitis in Remission of JIA

• Uveitis can persist or first appear after JIA joints enter remission — ophthalmology surveillance must continue regardless of joint disease activity
• Drug taper in remission — adalimumab dose reduction or cessation attempted after ≥2 years of inactive uveitis; careful ophthalmology monitoring during any biologic taper

Bilateral vs Unilateral Active Uveitis

• Bilateral disease — systemic MTX and adalimumab preferred over sub-Tenon injections; avoids repeated bilateral injection procedures in children
• Asymmetric disease — more active eye drives treatment decisions; less active eye may achieve remission with topical treatment alone initially

Stewardship in JIA uveitis focuses on maintaining appropriate surveillance schedules, correct escalation through topical corticosteroids to MTX to adalimumab, avoiding etanercept in uveitis, and preventing long-term corticosteroid complications.

GP Role in JIA Uveitis

• Facilitate surveillance — actively remind families of ophthalmology appointment schedules; track attendance; contact ophthalmologist if appointments are missed
• Educate families — JIA uveitis is silent; no eye symptoms does NOT mean no eye disease; every appointment matters
• MTX monitoring — FBC and LFTs monthly for 3 months, then 3-monthly; growth monitoring 3–6 monthly
• Biologic monitoring — FBC and LFTs 3-monthly on adalimumab; IGRA annually; hold biologic and contact rheumatology for febrile illness
• IOP awareness — if a child on topical steroids presents with headache or visual change, suspect raised IOP and facilitate same-day ophthalmology review

JIA uveitis requires lifelong ophthalmological follow-up until the uveitis itself is confirmed in remission off treatment for at least 2 years. Joint remission does not justify cessation of uveitis surveillance.

• 01
  Ramanan AV, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis (SYCAMORE trial). Lancet. 2017;390(10103):1744–1755.
• 02
  Angeles-Han ST, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res. 2019;71(6):703–716.
• 03
  Heiligenhaus A, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany. Br J Ophthalmol. 2008;92(8):1103–1106.
• 04
  Jabs DA, et al. Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol. 2005;140(3):509–516.
• 05
  Petty RE, et al. ILAR classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
• 06
  Therapeutic Guidelines. Rheumatology. Melbourne: Therapeutic Guidelines Ltd; 2024.
• 07
  Pharmaceutical Benefits Scheme (PBS). Schedule of Pharmaceutical Benefits. Canberra: Department of Health; 2025.